Logo image of CELU

CELULARITY INC-A (CELU) Stock Fundamental Analysis

NASDAQ:CELU - US1511902041 - Common Stock

2.55 USD
-1.39 (-35.28%)
Last: 9/2/2025, 8:00:00 PM
2.55 USD
0 (0%)
Pre-Market: 9/3/2025, 4:20:53 AM
Fundamental Rating

2

Taking everything into account, CELU scores 2 out of 10 in our fundamental rating. CELU was compared to 542 industry peers in the Biotechnology industry. Both the profitability and financial health of CELU have multiple concerns. CELU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CELU had negative earnings in the past year.
CELU had a negative operating cash flow in the past year.
CELU had negative earnings in 4 of the past 5 years.
CELU had a negative operating cash flow in each of the past 5 years.
CELU Yearly Net Income VS EBIT VS OCF VS FCFCELU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -43.62%, CELU is in line with its industry, outperforming 55.72% of the companies in the same industry.
With a Return On Equity value of -654.96%, CELU is not doing good in the industry: 79.89% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -43.62%
ROE -654.96%
ROIC N/A
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
CELU Yearly ROA, ROE, ROICCELU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

CELU's Gross Margin of 72.36% is amongst the best of the industry. CELU outperforms 82.29% of its industry peers.
CELU's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CELU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
CELU Yearly Profit, Operating, Gross MarginsCELU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

CELU does not have a ROIC to compare to the WACC, probably because it is not profitable.
CELU has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CELU has been increased compared to 5 years ago.
Compared to 1 year ago, CELU has a worse debt to assets ratio.
CELU Yearly Shares OutstandingCELU Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CELU Yearly Total Debt VS Total AssetsCELU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

CELU has an Altman-Z score of -10.03. This is a bad value and indicates that CELU is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.03, CELU is doing worse than 72.51% of the companies in the same industry.
A Debt/Equity ratio of 4.79 is on the high side and indicates that CELU has dependencies on debt financing.
With a Debt to Equity ratio value of 4.79, CELU is not doing good in the industry: 82.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 4.79
Debt/FCF N/A
Altman-Z -10.03
ROIC/WACCN/A
WACC7.82%
CELU Yearly LT Debt VS Equity VS FCFCELU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

CELU has a Current Ratio of 0.38. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.38, CELU is not doing good in the industry: 94.10% of the companies in the same industry are doing better.
CELU has a Quick Ratio of 0.38. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.28, CELU is not doing good in the industry: 94.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.28
CELU Yearly Current Assets VS Current LiabilitesCELU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

CELU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.46%, which is quite impressive.
The Revenue has grown by 138.11% in the past year. This is a very strong growth!
CELU shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.47% yearly.
EPS 1Y (TTM)76.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-210.43%
Revenue 1Y (TTM)138.11%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%49.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, CELU will show a very strong growth in Revenue. The Revenue will grow by 98.27% on average per year.
EPS Next Y26.32%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year233.89%
Revenue Next 2Y89.48%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CELU Yearly Revenue VS EstimatesCELU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CELU Yearly EPS VS EstimatesCELU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CELU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELU Price Earnings VS Forward Price EarningsCELU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELU Per share dataCELU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CELU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELULARITY INC-A

NASDAQ:CELU (9/2/2025, 8:00:00 PM)

Premarket: 2.55 0 (0%)

2.55

-1.39 (-35.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/amc
Earnings (Next)10-14 2025-10-14
Inst Owners14.68%
Inst Owner Change-0.55%
Ins Owners14.45%
Ins Owner Change0.04%
Market Cap61.07M
Analysts82.86
Price Target6.12 (140%)
Short Float %14.88%
Short Ratio5.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)140%
PT rev (3m)140%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.13
P/FCF N/A
P/OCF N/A
P/B 6.91
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.66
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS2.26
BVpS0.37
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.62%
ROE -654.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.36%
FCFM N/A
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 4.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.97%
Cap/Sales 3.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.28
Altman-Z -10.03
F-Score5
WACC7.82%
ROIC/WACCN/A
Cap/Depr(3y)39.96%
Cap/Depr(5y)N/A
Cap/Sales(3y)16.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-210.43%
EPS Next Y26.32%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)138.11%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%49.7%
Revenue Next Year233.89%
Revenue Next 2Y89.48%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%
EBIT growth 1Y-1173.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.45%
OCF growth 3YN/A
OCF growth 5YN/A